Q32 Bio (QTTB) Cash from Financing Activities (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Cash from Financing Activities of $8.8 million for Q1 2026, up 663.19% quarter-over-quarter from -$1.6 million in Q4 2025.
Q32 Bio (QTTB) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Q32 Bio's Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $8.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $6.0 million (changed N/A YoY), while the FY2025 annual figure was -$3.1 million, down 103.28% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $8.8 million, up from -$1.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $99.3 million in Q1 2024, with the low at -$5.5 million in Q2 2024.
- The 5-year median for Cash from Financing Activities is $100000.0 (2022), against an average of $7.3 million.
- Peak annual rise in Cash from Financing Activities reached 662206.67% in 2024, while the deepest fall reached 36913.33% in 2024.
- Q32 Bio's Cash from Financing Activities stood at $32000.0 in 2022, then jumped by 137.5% to $76000.0 in 2023, then jumped by 317.11% to $317000.0 in 2024, then slumped by 592.74% to -$1.6 million in 2025, then surged by 663.19% to $8.8 million in 2026.
- Business Quant data shows QTTB's Cash from Financing Activities at $8.8 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 58.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.59 Mn |
| Jun 30, 2026 | 58.59 Mn |
| Mar 31, 2026 | 8.80 Mn |
| Mar 31, 2026 | 8.80 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Dec 31, 2025 | -1.56 Mn |
| Sep 30, 2025 | -1.56 Mn |
| Sep 30, 2025 | -1.56 Mn |
| Dec 31, 2024 | 317,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Sep 30, 2024 | 997,000.00 |
| Sep 30, 2024 | 997,000.00 |
| Jun 30, 2024 | -5.52 Mn |
| Jun 30, 2024 | -5.52 Mn |
| Mar 31, 2024 | 99.35 Mn |
| Mar 31, 2024 | 99.35 Mn |
| Dec 31, 2023 | 76,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Sep 30, 2023 | 300,000.00 |